• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于多复合物药效团和分子对接的虚拟筛选混合协议发现新型粘着斑激酶抑制剂

Discovery of novel focal adhesion kinase inhibitors using a hybrid protocol of virtual screening approach based on multicomplex-based pharmacophore and molecular docking.

作者信息

Wu Fengbo, Xu Ting, He Gu, Ouyang Liang, Han Bo, Peng Cheng, Song Xiangrong, Xiang Mingli

机构信息

Department of Pharmacy and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.

出版信息

Int J Mol Sci. 2012 Nov 23;13(12):15668-78. doi: 10.3390/ijms131215668.

DOI:10.3390/ijms131215668
PMID:23443087
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3546655/
Abstract

Focal adhesion kinase (FAK) is a tyrosine kinase that functions as a key orchestrator of signals leading to invasion and metastasis. In the current study, the multicomplex-based pharmacophore (MCBP)-guided method has been suggested to generate a comprehensive pharmacophore of FAK kinase based on seven crystal structures of FAK-inhibitor complexes. In this investigation, a hybrid protocol of virtual screening methods, comprising of pharmacophore model-based virtual screening (PB-VS) and docking-based virtual screening (DB-VS), is used for retrieving new FAK inhibitors from commercially available chemical databases. This hybrid virtual screening approach was then applied to screen several chemical databases, including the Specs (202,408 compounds) database. Thirty-five compounds were selected from the final hits and should be shifted to experimental studies. These results may provide important information for further research of novel FAK inhibitors.

摘要

粘着斑激酶(FAK)是一种酪氨酸激酶,在导致侵袭和转移的信号传导中起关键协调作用。在本研究中,基于多复合物的药效团(MCBP)引导方法被用于根据FAK抑制剂复合物的七个晶体结构生成FAK激酶的综合药效团。在这项研究中,一种虚拟筛选方法的混合方案,包括基于药效团模型的虚拟筛选(PB-VS)和基于对接的虚拟筛选(DB-VS),被用于从商业化学数据库中检索新的FAK抑制剂。然后,这种混合虚拟筛选方法被应用于筛选几个化学数据库,包括Specs(202,408种化合物)数据库。从最终命中物中选择了35种化合物,并应转向实验研究。这些结果可能为新型FAK抑制剂的进一步研究提供重要信息。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4100/3546655/0b3951c6c6a3/ijms-13-15668f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4100/3546655/da2c7e359c38/ijms-13-15668f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4100/3546655/603fc00c7b94/ijms-13-15668f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4100/3546655/d459b514aab2/ijms-13-15668f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4100/3546655/0303c613876f/ijms-13-15668f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4100/3546655/0b3951c6c6a3/ijms-13-15668f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4100/3546655/da2c7e359c38/ijms-13-15668f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4100/3546655/603fc00c7b94/ijms-13-15668f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4100/3546655/d459b514aab2/ijms-13-15668f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4100/3546655/0303c613876f/ijms-13-15668f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4100/3546655/0b3951c6c6a3/ijms-13-15668f5.jpg

相似文献

1
Discovery of novel focal adhesion kinase inhibitors using a hybrid protocol of virtual screening approach based on multicomplex-based pharmacophore and molecular docking.基于多复合物药效团和分子对接的虚拟筛选混合协议发现新型粘着斑激酶抑制剂
Int J Mol Sci. 2012 Nov 23;13(12):15668-78. doi: 10.3390/ijms131215668.
2
Discovery of novel Bruton's tyrosine kinase inhibitors using a hybrid protocol of virtual screening approaches based on SVM model, pharmacophore and molecular docking.基于 SVM 模型、药效基团和分子对接的混合虚拟筛选方法发现新型布鲁顿酪氨酸激酶抑制剂。
Chem Biol Drug Des. 2012 Sep;80(3):366-73. doi: 10.1111/j.1747-0285.2012.01415.x. Epub 2012 Jun 27.
3
Novel hybrid virtual screening protocol based on molecular docking and structure-based pharmacophore for discovery of methionyl-tRNA synthetase inhibitors as antibacterial agents.基于分子对接和基于结构的药效团的新型混合虚拟筛选协议,用于发现作为抗菌剂的甲硫氨酰-tRNA合成酶抑制剂。
Int J Mol Sci. 2013 Jul 9;14(7):14225-39. doi: 10.3390/ijms140714225.
4
Optimization of virtual screening against phosphoinositide 3-kinase delta: Integration of common feature pharmacophore and multicomplex-based molecular docking.针对磷酸肌醇3激酶δ的虚拟筛选优化:共同特征药效团与基于多复合物的分子对接的整合
Comput Biol Chem. 2024 Apr;109:108011. doi: 10.1016/j.compbiolchem.2023.108011. Epub 2024 Jan 2.
5
Computational insights into allosteric inhibition of focal adhesion kinase: A combined pharmacophore modeling and molecular dynamics approach.粘着斑激酶变构抑制的计算洞察:一种结合药效团建模和分子动力学的方法。
J Mol Graph Model. 2024 Jul;130:108789. doi: 10.1016/j.jmgm.2024.108789. Epub 2024 May 4.
6
Structure-Based Virtual Screening, Synthesis and Biological Evaluation of Potential FAK-FAT Domain Inhibitors for Treatment of Metastatic Cancer.基于结构的虚拟筛选、合成及潜在 FAK-FAT 结构域抑制剂的生物学评价用于转移性癌症治疗
Molecules. 2020 Jul 31;25(15):3488. doi: 10.3390/molecules25153488.
7
An Integrated In Silico Method to Discover Novel Rock1 Inhibitors: Multi- Complex-Based Pharmacophore, Molecular Dynamics Simulation and Hybrid Protocol Virtual Screening.一种发现新型Rock1抑制剂的计算机辅助综合方法:基于多复合物的药效团、分子动力学模拟及混合协议虚拟筛选
Comb Chem High Throughput Screen. 2016;19(1):36-50. doi: 10.2174/1386207319666151203001946.
8
Identification of CK2 inhibitors with new scaffolds by a hybrid virtual screening approach based on Bayesian model; pharmacophore hypothesis and molecular docking.基于贝叶斯模型;药效团假说和分子对接的混合虚拟筛选方法鉴定新型骨架 CK2 抑制剂。
J Mol Graph Model. 2012 Jun;36:42-7. doi: 10.1016/j.jmgm.2012.03.004. Epub 2012 Mar 26.
9
Prediction of Toxoplasma gondii virulence factor ROP18 competitive inhibitors by virtual screening.通过虚拟筛选预测刚地弓形虫毒力因子 ROP18 竞争抑制剂。
Parasit Vectors. 2019 Mar 13;12(1):98. doi: 10.1186/s13071-019-3341-y.
10
Pharmacophore modeling and hybrid virtual screening for the discovery of novel IκB kinase 2 (IKK2) inhibitors.基于药效团模型的新型 IκB 激酶 2(IKK2)抑制剂的混合虚拟筛选。
J Biomol Struct Dyn. 2011 Aug;29(1):165-79. doi: 10.1080/07391102.2011.10507381.

引用本文的文献

1
Discovery of novel potential 11β-HSD1 inhibitors through combining deep learning, molecular modeling, and bio-evaluation.通过结合深度学习、分子建模和生物评估发现新型潜在11β-羟基类固醇脱氢酶1抑制剂
Mol Divers. 2025 May 21. doi: 10.1007/s11030-025-11171-0.
2
Drug Discovery Targeting Focal Adhesion Kinase (FAK) as a Promising Cancer Therapy.靶向黏着斑激酶(FAK)的药物研发:一种有前景的癌症治疗策略。
Molecules. 2021 Jul 13;26(14):4250. doi: 10.3390/molecules26144250.
3
Pharmacophore-driven identification of N-methyl-D-receptor antagonists as potent neuroprotective agents validated using studies.

本文引用的文献

1
Combined structure-based pharmacophore and 3D-QSAR studies on phenylalanine series compounds as TPH1 inhibitors.基于结构的药效团与3D-QSAR联合研究苯丙氨酸系列化合物作为色氨酸羟化酶1抑制剂的作用
Int J Mol Sci. 2012;13(5):5348-5363. doi: 10.3390/ijms13055348. Epub 2012 May 2.
2
ZINC: a free tool to discover chemistry for biology.ZINC:一款用于生物学的免费化学发现工具。
J Chem Inf Model. 2012 Jul 23;52(7):1757-68. doi: 10.1021/ci3001277. Epub 2012 Jun 15.
3
Multicomplex-based pharmacophore-guided 3D-QSAR studies of N-substituted 2'-(aminoaryl)benzothiazoles as Aurora-A inhibitors.
通过药效团驱动鉴定N-甲基-D-受体拮抗剂作为有效的神经保护剂,并通过研究进行验证。
Biol Methods Protoc. 2020 Jul 14;5(1):bpaa013. doi: 10.1093/biomethods/bpaa013. eCollection 2020.
4
Synergistic Interactions of 5-Fluorouracil with Inhibitors of Protein Kinase CK2 Correlate with p38 MAPK Activation and FAK Inhibition in the Triple-Negative Breast Cancer Cell Line.5-氟尿嘧啶与蛋白激酶 CK2 抑制剂的协同作用与 p38 MAPK 激活和三阴性乳腺癌细胞系中 FAK 抑制相关。
Int J Mol Sci. 2020 Aug 28;21(17):6234. doi: 10.3390/ijms21176234.
5
Comparing pharmacophore models derived from crystallography and NMR ensembles.比较源自晶体学和核磁共振集合的药效团模型。
J Comput Aided Mol Des. 2017 Nov;31(11):979-993. doi: 10.1007/s10822-017-0077-7. Epub 2017 Oct 19.
6
Combining structure-based pharmacophore modeling, virtual screening, and in silico ADMET analysis to discover novel tetrahydro-quinoline based pyruvate kinase isozyme M2 activators with antitumor activity.结合基于结构的药效团建模、虚拟筛选和计算机辅助药物代谢动力学/药物毒性分析,以发现具有抗肿瘤活性的新型基于四氢喹啉的丙酮酸激酶同工酶M2激活剂。
Drug Des Devel Ther. 2014 Sep 2;8:1195-210. doi: 10.2147/DDDT.S62921. eCollection 2014.
7
Novel hybrid virtual screening protocol based on molecular docking and structure-based pharmacophore for discovery of methionyl-tRNA synthetase inhibitors as antibacterial agents.基于分子对接和基于结构的药效团的新型混合虚拟筛选协议,用于发现作为抗菌剂的甲硫氨酰-tRNA合成酶抑制剂。
Int J Mol Sci. 2013 Jul 9;14(7):14225-39. doi: 10.3390/ijms140714225.
基于多复合物的药效团导向的 N-取代 2'-(氨基芳基)苯并噻唑类 Aurora-A 抑制剂的 3D-QSAR 研究。
Chem Biol Drug Des. 2012 Jun;79(6):960-71. doi: 10.1111/j.1747-0285.2012.01366.x. Epub 2012 Apr 17.
4
Potential virtual lead identification in the discovery of renin inhibitors: application of ligand and structure-based pharmacophore modeling approaches.潜在虚拟先导化合物鉴定在肾素抑制剂发现中的应用:配体和基于结构的药效团模型方法的应用。
Eur J Med Chem. 2011 Jun;46(6):2469-76. doi: 10.1016/j.ejmech.2011.03.035. Epub 2011 Mar 25.
5
Polarizable water molecules in ligand-macromolecule recognition. Impact on the relative affinities of competing pyrrolopyrimidine inhibitors for FAK kinase.配体-大分子识别中的可极化水分子。对 FAK 激酶的竞争吡咯并嘧啶抑制剂相对亲和力的影响。
J Am Chem Soc. 2010 Mar 17;132(10):3312-20. doi: 10.1021/ja9059156.
6
3D-QSAR studies of arylcarboxamides with inhibitory activity on InhA using pharmacophore-based alignment.基于药效团的叠合方法研究具有 InhA 抑制活性的芳基羧酰胺类化合物的 3D-QSAR
Chem Biol Drug Des. 2010 Feb;75(2):195-203. doi: 10.1111/j.1747-0285.2009.00926.x. Epub 2009 Dec 17.
7
Focal adhesion kinase as potential target for cancer therapy (Review).黏着斑激酶作为癌症治疗的潜在靶点(综述)。
Oncol Rep. 2009 Nov;22(5):973-9. doi: 10.3892/or_00000524.
8
Consensus superiority of the pharmacophore-based alignment, over maximum common substructure (MCS): 3D-QSAR studies on carbamates as acetylcholinesterase inhibitors.基于药效团比对相对于最大共同子结构(MCS)的共识优势:作为乙酰胆碱酯酶抑制剂的氨基甲酸酯类的3D-QSAR研究。
J Chem Inf Model. 2009 Jun;49(6):1590-601. doi: 10.1021/ci900049e.
9
Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation.细胞核黏着斑激酶通过FERM增强的p53降解促进细胞增殖和存活。
Mol Cell. 2008 Jan 18;29(1):9-22. doi: 10.1016/j.molcel.2007.11.031.
10
Focal adhesion kinase and p53 signaling in cancer cells.癌细胞中的粘着斑激酶与p53信号传导
Int Rev Cytol. 2007;263:103-53. doi: 10.1016/S0074-7696(07)63003-4.